Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics.

Leung F, Bernardini MQ, Liang K, Batruch I, Rouzbahman M, Diamandis EP, Kulasingam V.

Version 2. F1000Res. 2018 Feb 14 [revised 2018 Jan 1];7:189. doi: 10.12688/f1000research.13863.2. eCollection 2018.

2.

Towards personalized tumor markers.

Kulasingam V, Prassas I, Diamandis EP.

NPJ Precis Oncol. 2017 May 25;1(1):17. doi: 10.1038/s41698-017-0021-2. eCollection 2017.

3.

Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer.

Fung AWS, Knauer MJ, Blasutig IM, Colantonio DA, Kulasingam V.

Version 2. F1000Res. 2017 Oct 13 [revised 2017 Jan 1];6:1832. doi: 10.12688/f1000research.12775.2. eCollection 2017.

4.

A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic "nephrotic pattern" or skewed free light chain ratio.

Truong D, Blasutig IM, Kulasingam V, Chan PC.

Clin Biochem. 2018 Jan;51:110-111. doi: 10.1016/j.clinbiochem.2017.06.012. Epub 2017 Jul 1. No abstract available.

PMID:
28676334
5.

Urinary adenosine excretion in type 1 diabetes.

Rajasekeran H, Lytvyn Y, Bozovic A, Lovshin JA, Diamandis E, Cattran D, Husain M, Perkins BA, Advani A, Reich HN, Kulasingam V, Cherney DZI.

Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F184-F191. doi: 10.1152/ajprenal.00043.2017. Epub 2017 Apr 5.

PMID:
28381459
7.

The Use of Targeted Therapies for Precision Medicine in Oncology.

White Al-Habeeb N, Kulasingam V, Diamandis EP, Yousef GM, Tsongalis GJ, Vermeulen L, Zhu Z, Kamel-Reid S.

Clin Chem. 2016 Dec;62(12):1556-1564. Epub 2016 Sep 27. No abstract available.

8.

Major milestones in translational oncology.

Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA.

BMC Med. 2016 Jul 28;14(1):110. doi: 10.1186/s12916-016-0654-y.

9.

Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.

Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, Davis G, Serra S, Diamandis EP, Kulasingam V.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.

10.

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?

Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, Alix-Panabières C.

Clin Chem. 2016 Aug;62(8):1054-60. doi: 10.1373/clinchem.2016.260331. Epub 2016 Jun 3. No abstract available.

11.

Accuracy of testosterone concentrations in compounded testosterone products.

Grober ED, Garbens A, Božović A, Kulasingam V, Fanipour M, Diamandis EP.

J Sex Med. 2015 Jun;12(6):1381-8. doi: 10.1111/jsm.12898. Epub 2015 May 12.

PMID:
25963000
12.

Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?

Lennox GK, Eiriksson LR, Reade CJ, Leung F, Mojtahedi G, Atenafu EG, Ferguson SE, Murphy J, Diamandis EP, Kulasingam V, Bernardini MQ.

Int J Gynecol Cancer. 2015 Jun;25(5):809-14. doi: 10.1097/IGC.0000000000000442.

PMID:
25855958
13.

Ovarian cancer biomarkers: current state and future implications from high-throughput technologies.

Leung F, Diamandis EP, Kulasingam V.

Adv Clin Chem. 2014;66:25-77. Review.

PMID:
25344985
14.

Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

Smith CR, Batruch I, Bauça JM, Kosanam H, Ridley J, Bernardini MQ, Leung F, Diamandis EP, Kulasingam V.

Clin Proteomics. 2014 Jun 2;11(1):23. doi: 10.1186/1559-0275-11-23. eCollection 2014.

15.

Deciphering the ovarian cancer ascites fluid peptidome.

Bery A, Leung F, Smith CR, Diamandis EP, Kulasingam V.

Clin Proteomics. 2014 Apr 2;11(1):13. doi: 10.1186/1559-0275-11-13.

16.

Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1.

Niederkofler EE, Phillips DA, Krastins B, Kulasingam V, Kiernan UA, Tubbs KA, Peterman SM, Prakash A, Diamandis EP, Lopez MF, Nedelkov D.

PLoS One. 2013 Nov 21;8(11):e81125. doi: 10.1371/journal.pone.0081125. eCollection 2013.

17.

False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja CC, Brand R, Kulasingam V, Blasutig IM, Diamandis EP.

Clin Chem. 2014 Feb;60(2):381-8. doi: 10.1373/clinchem.2013.215236. Epub 2013 Oct 4.

18.

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.

19.

Fascin-1 is a novel biomarker of aggressiveness in some carcinomas.

Kulasingam V, Diamandis EP.

BMC Med. 2013 Feb 26;11:53. doi: 10.1186/1741-7015-11-53.

20.

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, Nelson R, Vogelsang MS, Vadali G, Garces A, Sutton JN, Peterman S, Byram G, Darbouret B, Pérusse JR, Seidah NG, Coulombe B, Gobom J, Portelius E, Pannee J, Blennow K, Kulasingam V, Couchman L, Moniz C, Lopez MF.

Clin Biochem. 2013 Apr;46(6):399-410. doi: 10.1016/j.clinbiochem.2012.12.019. Epub 2013 Jan 8.

21.

From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.

Leung F, Diamandis EP, Kulasingam V.

Biomark Med. 2012 Oct;6(5):613-25. doi: 10.2217/bmm.12.70. Review.

PMID:
23075239
22.

Quantitative mass spectrometry-based assay development and validation: from small molecules to proteins.

Božović A, Kulasingam V.

Clin Biochem. 2013 Apr;46(6):444-55. doi: 10.1016/j.clinbiochem.2012.09.024. Epub 2012 Oct 3. Review.

PMID:
23041077
23.

CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer.

Leung F, Soosaipillai A, Kulasingam V, Diamandis EP.

Clin Biochem. 2012 Dec;45(18):1543-6. doi: 10.1016/j.clinbiochem.2012.08.011. Epub 2012 Aug 17.

24.

Validating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurements.

Chan PC, Kulasingam V, Lem-Ragosnig B.

Clin Biochem. 2012 Nov;45(16-17):1533-5. doi: 10.1016/j.clinbiochem.2012.06.029. Epub 2012 Jul 5.

PMID:
22771504
25.

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Zhang H, Tian Y, Li Y, Kulasingam V, Drabovich A, Smith CR, Batruch I, Oran PE, Fredolini C, Luchini A, Liotta L, Petricoin E, Diamandis EP, Chan DW, Nelson R, Lopez MF.

J Proteome Res. 2012 Aug 3;11(8):3986-95. doi: 10.1021/pr300014s. Epub 2012 Jul 3.

26.

Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids.

Kulasingam V, Smith CR, Batruch I, Diamandis EP.

Methods Mol Biol. 2011;728:207-18. doi: 10.1007/978-1-61779-068-3_13.

PMID:
21468950
27.

Modification of the glucose correction factor by peritoneal dialysis solution type in the peritoneal equilibration test.

Perl J, Bargman JM, Kulasingam V, Yip PM.

Perit Dial Int. 2010 Nov-Dec;30(6):647-50. doi: 10.3747/pdi.2009.00213. No abstract available.

PMID:
21148057
28.

Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays.

Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, Russo P, Ross MM, Zhang H, Tian Y, Kulasingam V, Drabovich AP, Smith C, Batruch I, Liotta L, Petricoin E, Diamandis EP, Chan DW, Lopez MF.

J Proteome Res. 2010 Dec 3;9(12):6678-88. doi: 10.1021/pr100821m. Epub 2010 Nov 2.

PMID:
20945832
29.

Analytical evaluation of the VITROS 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals.

Blasutig IM, Jung B, Kulasingam V, Baradaran S, Chen Y, Chan MK, Colantonio D, Adeli K.

Clin Biochem. 2010 Sep;43(13-14):1039-44. doi: 10.1016/j.clinbiochem.2010.05.011. Epub 2010 May 23.

PMID:
20501331
30.

Pediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas 6000 analyzer--a CALIPER pilot study.

Kulasingam V, Jung BP, Blasutig IM, Baradaran S, Chan MK, Aytekin M, Colantonio DA, Adeli K.

Clin Biochem. 2010 Sep;43(13-14):1045-50. doi: 10.1016/j.clinbiochem.2010.05.008. Epub 2010 May 23.

PMID:
20501329
31.

Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.

Kulasingam V, Pavlou MP, Diamandis EP.

Nat Rev Cancer. 2010 May;10(5):371-8. doi: 10.1038/nrc2831. Epub 2010 Apr 12. Review.

PMID:
20383179
32.

Nipple aspirate fluid proteome of healthy females and patients with breast cancer.

Pavlou MP, Kulasingam V, Sauter ER, Kliethermes B, Diamandis EP.

Clin Chem. 2010 May;56(5):848-55. doi: 10.1373/clinchem.2009.136283. Epub 2010 Mar 26.

33.

Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.

Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP.

Mol Cell Proteomics. 2009 Dec;8(12):2746-58. doi: 10.1074/mcp.M900134-MCP200. Epub 2009 Sep 23.

34.

Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP.

Int J Cancer. 2009 Jul 1;125(1):9-14. doi: 10.1002/ijc.24292.

35.

Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP.

Mol Cell Proteomics. 2009 Apr;8(4):661-9. doi: 10.1074/mcp.M800313-MCP200. Epub 2008 Dec 1.

36.

Tissue culture-based breast cancer biomarker discovery platform.

Kulasingam V, Diamandis EP.

Int J Cancer. 2008 Nov 1;123(9):2007-12. doi: 10.1002/ijc.23844. Review.

37.

Strategies for discovering novel cancer biomarkers through utilization of emerging technologies.

Kulasingam V, Diamandis EP.

Nat Clin Pract Oncol. 2008 Oct;5(10):588-99. doi: 10.1038/ncponc1187. Epub 2008 Aug 12. Review.

PMID:
18695711
38.

"Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap.

Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, Diamandis EP.

J Proteome Res. 2008 Feb;7(2):640-7. doi: 10.1021/pr7005999. Epub 2008 Jan 11.

PMID:
18186600
39.

Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines.

Kulasingam V, Diamandis EP.

Biol Chem. 2007 Oct;388(10):1113-9.

PMID:
17937626
40.

Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets.

Kulasingam V, Diamandis EP.

Mol Cell Proteomics. 2007 Nov;6(11):1997-2011. Epub 2007 Jul 25.

41.

Recycling of the membrane-anchored chemokine, CX3CL1.

Liu GY, Kulasingam V, Alexander RT, Touret N, Fong AM, Patel DD, Robinson LA.

J Biol Chem. 2005 May 20;280(20):19858-66. Epub 2005 Mar 16.

Supplemental Content

Loading ...
Support Center